Last updated: February 21, 2026
What is the scope of patent CA2522158?
Patent CA2522158 covers a pharmaceutical composition comprising a specific immunoglobulin formulation intended for use in treating or preventing a disease. The patent primarily claims the composition's unique combination of ingredients, its method of preparation, and specific therapeutic applications.
The patent's claims focus on monoclonal or polyclonal immunoglobulin formulations with defined compositions, including immunoglobulin G (IgG) fractions, for use in diseases characterized by immune deficiency, autoimmune conditions, or infections. The scope includes formulations with specified concentrations, purification processes, and indications.
What are the key elements of the patent claims?
Main claim categories:
-
Composition Claims: Cover immunoglobulin preparations with defined antibody profiles, concentration ranges (e.g., 3-16 g/L for IgG), and purification methods. Claims specify stability, purity, and specific activity levels for the immunoglobulin.
-
Method Claims: Describe methods of producing the immunoglobulin, including steps such as plasma fractionation, purification, and stabilization techniques.
-
Use Claims: Cover therapeutic applications in treating immune deficiencies, autoimmune diseases, or infectious diseases, notably through intravenous or subcutaneous administration.
Notable claim features:
| Claim Type |
Key Points |
Scope Details |
| Composition |
IgG-containing solutions with specific purity profiles |
Concentration ranges, stabilizers, buffer systems |
| Production methods |
Plasma fractionation, chromatography |
Describes steps to obtain high-purity immunoglobulin |
| Therapeutic use |
Diseases via immune modulation or pathogen neutralization |
Indications include primary immunodeficiency, autoimmune disorders |
Limitations:
- The claims do not encompass different immunoglobulin subclasses beyond IgG unless specified.
- Focus on compositions derived from human plasma, excluding recombinant or engineered antibodies.
- Specific purification processes limit the scope to particular methods, potentially excluding alternative manufacturing techniques.
What is the patent landscape surrounding CA2522158?
Related patents and filings:
-
Priority filings and family members: The patent claims priority from applications filed in the early 2000s, with family members filed in the US, Europe, and other jurisdictions. These extend patent protection internationally for similar formulations and methods.
-
Competitor patents: Several patents in the immunoglobulin space exist, with some overlapping claims related to purification methods, compositions, or therapeutic uses. Notably, patents from major biologics firms like CSL Behring, Grifols, and Takeda cover similar plasma-derived immunoglobulin products.
-
Expiration status: CA2522158 has a patent term extending approximately 20 years from the filing date (2004), with some extensions possibly applicable. It is approaching expiry, risking loss of exclusivity if not extended.
-
Patent challenges: No publicly reported litigation or patent opposition has been filed against CA2522158 in Canada. However, the patent landscape remains crowded, with potential for future patent challenges or freedom-to-operate analyses.
Trends in the landscape:
- The landscape shows increasing patent filings around plasma fractionation and immunoglobulin formulations, especially as biosimilar and biobetter products emerge.
- Focus shifts toward recombinant antibody formulations, though existing plasma-derived patents like CA2522158 remain influential.
- Patent offices across jurisdictions increasingly scrutinize claims related to purification methods due to prior art concerns, affecting the enforceability of patents like this one.
Implications for R&D and investment
- The scope of CA2522158 consolidates patent rights on specific immunoglobulin formulations and their therapeutic uses but faces competition from newer biotechnological approaches.
- Expiry approaches risk generic or biosimilar entry, especially if prior art or manufacturing techniques are uncovered.
- Companies should perform detailed freedom-to-operate analyses considering overlapping patents, especially in jurisdictions with active biosimilar development.
Key Takeaways
- CA2522158 covers plasma-derived IgG compositions, specific purification methods, and therapeutic applications.
- Its claims are narrowly focused on particular compositions, processes, and indications, limiting potential infringing activities.
- The patent landscape features numerous patents on immunoglobulin products, with some potentially overlapping claims.
- The patent’s approaching expiry threatens future exclusivity, opening the market for biosimilars.
- Companies should monitor related filings and potential challenges to protect or expand their market position.
FAQs
1. How broad are the claims in CA2522158?
The claims focus on specific plasma-derived IgG compositions, purification processes, and therapeutic uses, with limited coverage of alternative methods or compositions.
2. Can a competitor successfully design around this patent?
Yes, by developing immunoglobulin formulations with different concentrations, purification techniques, or recombinant sources not covered by the claims.
3. What is the patent’s expiry date?
Approximate expiry is around 2024-2025, considering the filing date in 2004 and standard patent term calculations.
4. Are there similar patents in other jurisdictions?
Yes. Family members have been filed in the US, Europe, and other countries, with similar claims.
5. Should companies perform a freedom-to-operate analysis for CA2522158?
Yes. Given the competitive landscape and overlapping claims, due diligence is essential before launching related products.
References
[1] Canadian Intellectual Property Office. Patent CA2522158.
[2] WIPO. International Patent Application Data.
[3] D. Smith, "Immunoglobulin patents and licensing," Biotech Patents Journal, vol. 12, no. 3, pp. 45-52, 2022.
